Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Short Interest Update

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,755,818 shares, an increase of 47.9% from the December 15th total of 1,187,068 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 310,403 shares, the days-to-cover ratio is presently 5.7 days. Based on an average daily volume of 310,403 shares, the days-to-cover ratio is presently 5.7 days. Approximately 0.3% of the shares of the company are sold short.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Several institutional investors and hedge funds have recently modified their holdings of FMS. TD Waterhouse Canada Inc. acquired a new position in Fresenius Medical Care AG & Co. KGaA in the 2nd quarter worth about $36,000. CIBC Private Wealth Group LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after acquiring an additional 1,103 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter valued at approximately $43,000. Hantz Financial Services Inc. grew its holdings in Fresenius Medical Care AG & Co. KGaA by 568.5% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock valued at $59,000 after buying an additional 1,768 shares in the last quarter. Finally, Huntington National Bank increased its position in Fresenius Medical Care AG & Co. KGaA by 219.5% during the second quarter. Huntington National Bank now owns 2,355 shares of the company’s stock worth $67,000 after purchasing an additional 1,618 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of NYSE:FMS traded up $0.37 during trading on Friday, hitting $22.00. 1,845,082 shares of the stock traded hands, compared to its average volume of 393,797. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 0.45. The company has a fifty day moving average price of $23.42 and a two-hundred day moving average price of $25.07. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $21.02 and a 52-week high of $30.46. The company has a market cap of $12.91 billion, a price-to-earnings ratio of 16.06, a P/E/G ratio of 0.70 and a beta of 0.90.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%. The firm had revenue of $5.73 billion for the quarter, compared to the consensus estimate of $4.72 billion. As a group, equities analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on FMS shares. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 5th. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Finally, Truist Financial set a $28.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Three equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $28.00.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.